Ginkgo Bioworks Holdings, Inc. (DNA) Key Statistics & Metrics

Ginkgo Bioworks Holdings, Inc. (DNA) has an ST Score of 39.9 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate DNA a Buy, with a price target of $5.00 (-49.3% vs the current price). Our ST Score grades it C (39.9/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B-, Profitability B-, Financial Strength D+, Momentum B+, Growth C+, Forecast D-, Sentiment C.

Ginkgo Bioworks Holdings, Inc. (DNA) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Ginkgo Bioworks Holdings, Inc. (DNA) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Ginkgo Bioworks Holdings, Inc. (DNA) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Ginkgo Bioworks Holdings, Inc. (DNA) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Ginkgo Bioworks Holdings, Inc. (DNA) is $5.00 from 11 analysts, which is -49.3% versus the recent price of $9.86.

Ginkgo Bioworks Holdings, Inc. (DNA) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.